Eli Frydman
Directeur/Membre du Conseil chez LifeBond Ltd.
Profil
Eli Frydman is currently a Director at LifeBond Ltd.
He previously held Director positions at Beta-O2 Technologies Ltd., PolyPid Ltd., and Nucleix Ltd.
He also served as COO & Vice President-Business Development at Aposense Ltd.
in 2011.
Frydman holds an MBA and a doctorate from Ecole Nationale des Ponts et Chaussées.
He also has an undergraduate degree from Tel-Aviv University and graduate and doctorate degrees from Weizmann Institute of Science.
Postes actifs de Eli Frydman
| Sociétés | Poste | Début |
|---|---|---|
LifeBond Ltd.
 LifeBond Ltd. Medical SpecialtiesHealth Technology LifeBond Ltd. engages in the development of medical devices designed to restore and repair tissues to reduce post-operative complications. The company was founded by Nir Mashkif, Orahn Preiss-Bloom and Ishay Attar in 2007 and is headquartered in Caesarea, Israel. | Directeur/Membre du Conseil | - |
Anciens postes connus de Eli Frydman
| Sociétés | Poste | Fin |
|---|---|---|
| POLYPID LTD. | Directeur/Membre du Conseil | - |
Beta-O2 Technologies Ltd.
 Beta-O2 Technologies Ltd. Medical SpecialtiesHealth Technology Beta-O2 Technologies Ltd. develops implantable bio-artificial pancreas devices. It offers BAir, a bio-artificial pancreas that provides a viable environment for islets of Langerhans to thrive and provide the body with insulin on demand. The company was founded by Pnina Vardi, Konstantin Bloch, and Yossi Gross in 2004 and is headquartered in Rosh-Haayin, Israel. | Directeur/Membre du Conseil | - |
Nucleix Ltd.
 Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Directeur/Membre du Conseil | - |
| APOSENSE LTD | Directeur des opérations | - |
Formation de Eli Frydman
| Ecole Nationale des Ponts et Chaussées | Doctorate Degree |
| Tel-Aviv University | Undergraduate Degree |
| Weizmann Institute of Science | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| POLYPID LTD. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Aposense Ltd.
 Aposense Ltd. Pharmaceuticals: MajorHealth Technology Aposense Ltd. engages in the provision of proprietary conjugates. It offers platform technology which comprises the rational design of small molecular moieties with the increased affinity to the cell membranes imparting the conjugates compound with improved drug properties such as extended life span oral bioavailabity and selective at target site. The company was founded by Ilan Ziv and Jacob Gottenstein on October 9, 1996 and is headquartered in Petach-Tikva, Israel. | Health Technology |
LifeBond Ltd.
LifeBond Ltd. Medical SpecialtiesHealth Technology LifeBond Ltd. engages in the development of medical devices designed to restore and repair tissues to reduce post-operative complications. The company was founded by Nir Mashkif, Orahn Preiss-Bloom and Ishay Attar in 2007 and is headquartered in Caesarea, Israel. | Health Technology |
Beta-O2 Technologies Ltd.
Beta-O2 Technologies Ltd. Medical SpecialtiesHealth Technology Beta-O2 Technologies Ltd. develops implantable bio-artificial pancreas devices. It offers BAir, a bio-artificial pancreas that provides a viable environment for islets of Langerhans to thrive and provide the body with insulin on demand. The company was founded by Pnina Vardi, Konstantin Bloch, and Yossi Gross in 2004 and is headquartered in Rosh-Haayin, Israel. | Health Technology |
Nucleix Ltd.
Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Health Services |
